Moderna Completes Enrollment in Large COVID-19 Vaccine Study

(Reuters) -
A nurse prepares a shot as a study of a possible COVID-19 vaccine, developed by the National Institutes of Health and Moderna Inc., gets underway in Binghamton, N.Y. (AP Photo/Hans Pennink)

Moderna Inc. said on Thursday it had completed the enrollment of 30,000 participants in a late-stage study testing its experimental coronavirus vaccine, with over a third of the participants from communities of color.

Over 25,650 participants have so far received their second shot of the vaccine candidate, mRNA-1273, the company said.

Moderna said its study includes more than 11,000 participants from minority communities, including 6,000 Hispanic or Latin-American participants and more than 3,000 Black or African-American participants.

The company said it would evaluate the study’s risks and benefits before submitting an emergency-use application for the vaccine to the U.S. health regulator.

The U.S. Food and Drug Administration requires at least two months of safety data after a full vaccination regime to review applications for emergency use authorization of an experimental vaccine.